Common questions about Komboglyze (FAQ)
Q: Are there different strengths of Komboglyze tablets available?
Yes, Komboglyze is available in multiple fixed-dose strengths from the manufacturer, combining different amounts of the two active ingredients, saxagliptin and metformin. Official product information lists several available dose forms, such as 2.5 mg/850 mg and 2.5 mg/1,000 mg combinations.
Q: Is there a generic version of Komboglyze available?
Yes, according to information from the U.S. Food and Drug Administration (FDA), generic versions of the combined medicine (saxagliptin and metformin hydrochloride extended-release) have been approved and are available from various manufacturers.
Q: Does Komboglyze interact with common over-the-counter pain relievers?
Official drug labels indicate that some common over-the-counter pain relievers, specifically NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), are substances the use of which is noted to require caution in official documentation. NSAIDs can temporarily reduce kidney function, which may increase the risk of lactic acidosis, a rare but serious side effect associated with the metformin component.
Q: Is Komboglyze used for pre-diabetes?
No. According to the official regulatory documents, Komboglyze is indicated only for use in adults with Type 2 Diabetes Mellitus. It is intended as an addition to diet and exercise to help manage high blood sugar, and its use for pre-diabetes is not an approved indication.
Q: Are there any restrictions on driving or operating machinery while taking Komboglyze?
The medicine itself is not known to directly affect a person’s ability to drive or use machines. However, official information suggests considering the potential for hypoglycemia (low blood sugar), especially if Komboglyze is taken alongside other medications that lower blood sugar, like insulin or a sulfonylurea.
Q: Does Komboglyze make you tired?
Unusual tiredness or fatigue is not listed as a common or very common side effect in the official safety profile. However, unusual tiredness is listed as a potential symptom of the rare but serious complication lactic acidosis and can also be a symptom of heart failure, both of which are serious safety concerns noted in the official labeling.
Q: Does Komboglyze have a black box warning in the US regulatory documents?
Yes, the U.S. Prescribing Information contains a Boxed Warning (often called a 'Black Box Warning') regarding the risk of lactic acidosis. This is a rare, life-threatening buildup of acid in the blood associated with the metformin component, and is a major focus of regulatory warnings.
Q: Is there a patient information leaflet available for Komboglyze?
Yes, regulatory agencies require that a patient-specific document, such as a Medication Guide or Patient Information Leaflet, be available for this medicine. This official document contains important information for patients regarding the use of the medicine, as required by regulatory bodies.
Q: Can Komboglyze be taken with other diabetes medications?
Yes, regulatory documents indicate that Komboglyze can be used in combination with other diabetes treatments, such as insulin or a sulfonylurea. Co-administration may result in an increased risk of hypoglycemia, and official information indicates that a dosage adjustment of the insulin or sulfonylurea may be necessary.
Q: Are there any specific foods or drinks to avoid while taking Komboglyze?
The most specific and serious warning regarding consumption involves alcohol. Official product information includes a warning against excessive alcohol intake while using this medicine. This is because alcohol can potentiate the effects of metformin on lactate metabolism, thereby increasing the risk of lactic acidosis.
Q: What is the expected long-term effect of Komboglyze on the body?
Long-term studies focus primarily on two key areas: sustained glycemic control (lowering HbA1c) and cardiovascular safety. While a large, long-term trial (SAVOR-TIMI 53) found no overall difference in a composite of major cardiovascular events, it did observe a higher rate of hospitalization for heart failure in some patients receiving saxagliptin.
Q: Can Komboglyze affect fertility or pregnancy planning?
The safety of this medicine during pregnancy or breastfeeding is not established in humans. Use during pregnancy or while breastfeeding is reserved only for cases where the benefit is considered clearly necessary, due to limited human data. Animal studies have indicated reproductive toxicity at high doses of saxagliptin. Metformin is known to be excreted into human milk, although the effect on a nursing infant is unknown.
Q: What are the signs of a severe allergic reaction to Komboglyze?
The official label describes symptoms associated with serious immune events like anaphylaxis or angioedema (severe swelling). These signs may include swelling of the face, lips, throat, or other body parts, as well as experiencing difficulty swallowing or breathing.
Q: Does taking Komboglyze require special monitoring or blood tests?
Yes, regulatory documents require specific monitoring. Due to the risks associated with the metformin component, kidney (renal) function must be assessed before and periodically during treatment. Additionally, long-term use of metformin may lead to lowered Vitamin B12 levels, and monitoring these levels may also be necessary.
Q: What should I know about the shelf life or storage of Komboglyze?
Official labeling dictates that the medicine should be stored at a controlled room temperature (e.g., 68 F to 77 F), protected from moisture and heat. The shelf life or expiration date for the product is printed directly on the container by the manufacturer.
Q: Can Komboglyze cause weight loss or weight gain?
According to the official summary of safety profiles, neither weight loss nor weight gain is listed as a commonly reported side effect or adverse reaction for the combined drug in clinical trials.
